Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Incyte (INCY) Weakness Seen Related to OPZELURA Sample 'Texture Issues' - Mizuho
November 2, 2021 11:02 AM EDTMizuho Securities analyst Mara Goldstein weighed in on Incyte (NASDAQ: INCY) following Q3 results and its earnings call. The analyst believes the weakness is likely related to management's comment on a texture issue associated with OPZELURA' (ruxolitinib cream) samples for atopic dermatitis (AD) and is under investigation... More
Incyte (INCY) Tops Q3 EPS by 46c
November 2, 2021 7:16 AM EDTIncyte (NASDAQ: INCY) reported Q3 EPS of $1.18, $0.46 better than the analyst estimate of $0.72. Revenue for the quarter came in at $813 million versus the consensus estimate of $738.52 million.
... More